TCT 2026 Top 7 Trials That Will Change Cath Lab Practice

TCT 2026: 7 Late-Breaking Trials That Will Change Cath Lab Practice (TRANSFORM II, PIVOT, CLASP II, PROGRESS) The episode recaps TCT 2026 in San Diego, selecting and ranking seven late-breaking interventional cardiology trials most likely to change practice, covering ANOCA therapy, left atrial appendage occlusion, heparin dosing during PCI, moderate aortic stenosis, transcatheter tricuspid repair, CT-guided PCI planning, and drug-coated balloons versus drug-eluting stents. It highlights REMEDY (coronary sinus reducer in microvascular ANOCA) showing safety but no benefit versus sham; SIMPLIFY finding aspirin monotherapy or reduced-dose apixaban non-inferior to 6-month DAPT after Watchman FLX PRO with less bleeding; Heparin Dose PCI supporting 70 U/kg over 100 U/kg to reduce bleeding without more thrombosis; PROGRESS showing TAVR reduced heart failure events in high-risk moderate AS; CLASP II showing PASCAL reduced TR and HF hospitalizations; PIVOT showing CT planning non-inferior to IVUS with shorter, lower-contrast PCI using specialized software; and TRANSFORM II showing sirolimus-coated balloons non-inferior to modern DES in de novo lesions with reduced cardiac mortality after successful lesion preparation. 00:00 TCT Highlights Overview 01:02 Trial 7 Coronary Sinus Reducer 03:21 Trial 6 LAAO Antithrombotics 05:41 Trial 5 Heparin Dosing PCI 07:35 Trial 4 TAVR Moderate AS 09:54 Trial 3 Tricuspid TEER CLASP 11:15 Trial 2 CCTA Guided PCI 14:23 Trial 1 DCB vs DES TRANSFORM 16:09 Wrap Up Key Takeaways